Intrahepatic Cholangiocarcinoma Clinical Trials in Boston, Massachusetts
4 recruitingBoston, Massachusetts
Showing 1–4 of 4 trials
Recruiting
Phase 2
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Phase 2
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
CholangiocarcinomaBile Duct CancerCholangiocarcinoma Non-resectable+2 more
Beth Israel Deaconess Medical Center30 enrolled1 locationNCT05655949
Recruiting
Phase 1Phase 2
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Phase 1
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Solid TumorIntrahepatic CholangiocarcinomaLocally Advanced Cholangiocarcinoma+1 more
Tyra Biosciences, Inc40 enrolled4 locationsNCT06160752